Our Work
Latham & Watkins Advises on Abivax's US$650 Million Public Offering
July 24, 2025
Capital Markets team represents the underwriters in the offering by the biotechnology company.
Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, has announced the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares (ADSs), each representing one ordinary share, €0.01 nominal value per share, in the United States at an offering price of US$64 per ADS.
Latham & Watkins LLP represents the underwriters in the transaction with a Capital Markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Sandy Kugbei, Connor Adams, and Kan Ni.